ECO Animal Health Reports Strong Revenue Growth as Global Demand for Livestock Health Products Increases

UK animal health company delivers double-digit sales growth, expands vaccine portfolio and strengthens confidence with CEO share purchase

LONDON, July 16, 2026: UK-based ECO Animal Health Group Plc has reported stronger financial results for the year ended March 31, 2026, reflecting continued demand for livestock health products and growing investment in preventive animal healthcare. The company also announced that Chief Executive Officer David Hallas has increased his personal shareholding, a move often viewed by investors as a sign of confidence in the company’s long-term strategy.

The results come as the global animal health industry places greater emphasis on disease prevention, poultry vaccines and sustainable livestock production.

Revenue rises 10% as profits improve

ECO Animal Health reported group revenue of £87.5 million, compared with £79.6 million in the previous financial year, representing 10% year-on-year growth.

The company also reported adjusted EBITDA of £8.5 million, up from £7.3 million a year earlier, reflecting a 16% increase in operating performance and exceeding market expectations.

The strong performance was supported by a better-than-expected second half of the financial year.

Livestock health remains the company’s core business

ECO Animal Health develops and markets veterinary medicines used primarily in poultry and pig production.

Its best-known product, Aivlosin®, is used to treat respiratory and intestinal diseases in pigs and poultry and is sold in more than 70 countries.

Alongside its established medicines, the company is investing heavily in vaccines and other preventive animal health products.

Poultry vaccine strategy gains momentum

One of the company’s biggest recent milestones has been the commercial launch of ECOVAXXIN® MS in the European Union.

The vaccine is designed to help protect poultry against Mycoplasma synoviae, a bacterial disease that can reduce egg production, affect growth and increase production losses in commercial flocks.

ECOVAXXIN MS is the first product from ECO Animal Health’s in-house research and development pipeline, marking an important step in the company’s strategy to expand beyond traditional medicines into preventive animal healthcare.

CEO increases personal investment

On July 16, CEO David Hallas purchased 22,346 additional ordinary shares in ECO Animal Health.

Following the purchase, his holding increased to 225,387 shares, representing approximately 0.33% of the company’s issued share capital.

While executive share purchases do not guarantee future business performance, they are generally regarded as a positive signal because senior management is investing their own capital in the business.

Animal health industry shifts toward prevention

Across the global livestock industry, veterinary companies are investing more heavily in vaccines, disease prevention and herd health management.

Preventing disease is increasingly recognised as a way to improve animal welfare, reduce production losses and support more responsible use of antibiotics.

ECO Animal Health’s growing vaccine portfolio reflects this broader trend.

Global livestock health market continues to expand

Demand for veterinary medicines is rising as livestock producers focus on improving productivity while protecting animal health.

Growing concerns over infectious diseases in poultry and pigs, combined with higher demand for animal protein, continue to support investment in veterinary medicines, vaccines and diagnostic technologies.

Companies with established livestock portfolios and expanding vaccine pipelines are expected to benefit from these long-term industry trends.

Positive outlook for ECO Animal Health

The latest financial results suggest that ECO Animal Health is successfully strengthening both its commercial business and its research pipeline.

With double-digit revenue growth, improved profitability, an expanding vaccine portfolio and continued investment by senior management, the company appears well positioned to benefit from the increasing global focus on preventive animal healthcare.

Eco Animal Health stock is listed on UK’s London Stock Exchange and closed at GBP 89.00 for the day – indicating a sideways movement.